Evidence map›Paper›PMID 33009361›Full record

ArticleThe American journal of case reports2020

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.

Joanna L Moore, Pavan V Ganapathiraju, Caroline P Kurtz, Booth Wainscoat

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2022
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. A case of COVID-19 Reinfection and Systematic Review of Patterns of Reinfection.Infectious diseases in clinical practice (Baltimore, Md.) · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Joanna L MooreDepartment of Medicine, Norwalk Hospital, Norwalk, CT, USA.
Pavan V GanapathirajuDepartment of Pulmonary and Critical Care Medicine, Norwalk Hospital, Yale School of Medicine, University of Vermont School of Medicine, Norwalk, CT, USA.
Caroline P KurtzDepartment of Pulmonary and Critical Care Medicine, Norwalk Hospital, Norwalk, CT, USA.
Booth WainscoatDepartment of Infectious Disease, Norwalk Hospital, Norwalk, CT, USA.
Norwalk Hospital · USUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND This is a case report of an immunocompromised patient with a history of non-Hodgkin lymphoma and persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who was seronegative and successfully treated with convalescent plasma. CASE REPORT A 63-year-old woman with a past medical history of non-Hodgkin lymphoma in remission while on maintenance therapy with the anti-CD20 monoclonal antibody, obinutuzumab, tested positive for SARS-CoV-2 via nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR) testing over 12 weeks and persistently tested seronegative for immunoglobulin G (IgG) antibodies using SARS-CoV-2 IgG chemiluminescent microparticle immunoassay technology. During this time, the patient experienced waxing and waning of symptoms, which included fever, myalgia, and non-productive cough, but never acquired severe respiratory distress. She was admitted to our hospital on illness day 88, and her symptoms resolved after the administration of convalescent plasma. CONCLUSIONS As the understanding of the pathogenesis of SARS-CoV-2 continues to evolve, we can currently only speculate about the occurrence of chronic infection vs. reinfection. The protective role of antibodies and their longevity against SARS-CoV-2 remain unclear. Since humoral immunity has an integral role in SARS-CoV-2 infection, various phase 3 vaccine trials are underway. In the context of this pandemic, the present case demonstrates the challenges in our understanding of testing and treating immunocompromised patients.

Indexed as

Immunocompromised HostAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 SerotherapyCOVID-19 TestingFemaleFollow-Up StudiesHumansImmunization, PassiveLymphoma, Non-HodgkinMiddle AgedPandemicsPneumonia, ViralAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalobinutuzumab

Identifiers

PMID33009361
PMCPMC7542548
OpenAlexW3088401606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.